RNA Editing MarketSize, Share & Industry Analysis, 2026-2034By TechnologyBy Edit TypeBy Delivery MethodBy OfferingBy Therapeutic AreaBy Target MechanismBy Development StageBy Route of AdministrationBy ApplicationBy End User
Full title & scope — all 10 axes with their segments
RNA Editing Market Size, Share & Industry Analysis, By Technology (ADAR-based RNA Editing, CRISPR-based RNA Editing, APOBEC-based RNA Editing, RNA Exon Editing, Chemical and Synthetic Editing Platforms, Epitranscriptomic Editing), By Edit Type (Adenosine-to-Inosine, Cytidine-to-Uridine, Exon Replacement, RNA Base Modification, Splicing Modulation), By Delivery Method (Lipid Nanoparticles, Adeno-Associated Virus Vectors, GalNAc Conjugates, Lentiviral Vectors, Electroporation, Other Non-viral Methods), By Offering (Therapeutic Candidates and Programs, Reagents and Kits, Instruments and Platforms, Software and Bioinformatics, Services), By Therapeutic Area (Rare Genetic Disorders, Neurological Disorders, Oncology, Ophthalmic Disorders, Cardiovascular and Metabolic Disorders, Infectious Diseases, Liver Diseases), By Target Mechanism (Correction of Pathogenic Point Mutations, Protein Upregulation, Protein Modulation, Start Codon and Stop Codon Editing, Post-translational Modification Site Editing, Splice Site Editing), By Development Stage (Discovery and Research, Preclinical, Phase I, Phase II, Phase III and Beyond), By Route of Administration (Intravenous, Subcutaneous, Intrathecal, Intravitreal, Intramuscular, Intracerebroventricular), By Application (Therapeutics Development, Drug Discovery and Target Validation, Basic and Translational Research, Diagnostics and Biomarker Development, Agricultural and Industrial Biotechnology), By End User (Biotechnology Companies, Pharmaceutical Companies, Academic and Research Institutes, Contract Research and Manufacturing Organizations, Hospitals and Specialty Clinics), and Regional Forecast, 2026-2034
Segment definitions and share of revenue by product, animal, end user and region.
Segmentation Analysis
10 axesBy Technology
6- 01ADAR-based RNA Editing
- 02CRISPR-based RNA Editing
- 03APOBEC-based RNA Editing (C-to-U)
- 04RNA Exon Editing (Trans-Splicing)
- 05Chemical and Synthetic Editing Platforms
- 06Epitranscriptomic Editing (m6A and Pseudouridine)
By Edit Type
5- 01Adenosine-to-Inosine (A-to-I)
- 02Cytidine-to-Uridine (C-to-U)
- 03Exon Replacement
- 04RNA Base Modification
- 05Splicing Modulation
By Delivery Method
6- 01Lipid Nanoparticles
- 02Adeno-Associated Virus Vectors
- 03GalNAc Conjugates
- 04Lentiviral Vectors
- 05Electroporation
- 06Other Non-viral Methods
By Offering
5- 01Therapeutic Candidates and Programs
- 02Reagents and Kits
- 03Instruments and Platforms
- 04Software and Bioinformatics
- 05Services
By Therapeutic Area
7- 01Rare Genetic Disorders
- 02Neurological Disorders
- 03Oncology
- 04Ophthalmic Disorders
- 05Cardiovascular and Metabolic Disorders
- 06Infectious Diseases
- 07Liver Diseases
By Target Mechanism
6- 01Correction of Pathogenic Point Mutations
- 02Protein Upregulation
- 03Protein Modulation
- 04Start Codon and Stop Codon Editing
- 05Post-translational Modification Site Editing
- 06Splice Site Editing
By Development Stage
5- 01Discovery and Research
- 02Preclinical
- 03Phase I
- 04Phase II
- 05Phase III and Beyond
By Route of Administration
6- 01Intravenous
- 02Subcutaneous
- 03Intrathecal
- 04Intravitreal
- 05Intramuscular
- 06Intracerebroventricular
By Application
5- 01Therapeutics Development
- 02Drug Discovery and Target Validation
- 03Basic and Translational Research
- 04Diagnostics and Biomarker Development
- 05Agricultural and Industrial Biotechnology
By End User
5- 01Biotechnology Companies
- 02Pharmaceutical Companies
- 03Academic and Research Institutes
- 04Contract Research and Manufacturing Organizations
- 05Hospitals and Specialty Clinics
Segment categories shown for scope reference. See the Summary tab for revenue share by Technology. Full segment-by-segment detail across every axis is available in the sample and full report.
Questions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the RNA Editing Market projected to reach?
USD 9.25 USD Billion by 2034, CAGR 19%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 50% of global revenue through 2034.
05Which segment leads the market?
ADAR-based RNA Editing is the largest line by technology, at 40% of revenue in 2025.
06Who are the key companies profiled?
Wave Life Sciences Ltd., Korro Bio, Inc., ProQR Therapeutics N.V., Shape Therapeutics Inc., Ascidian Therapeutics, Inc., AIRNA Corporation, Roche Holding AG, Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., Beam Therapeutics Inc., Editas Medicine, Inc., Intellia Therapeutics, Inc., CRISPR Therapeutics AG, Prime Medicine, Inc., Sarepta Therapeutics, Inc., Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Agilent Technologies, Inc., Integrated DNA Technologies, Inc., Twist Bioscience Corporation, GenScript Biotech Corporation, Eli Lilly and Company, Novo Nordisk A/S, Skyhawk Therapeutics, Inc., Rznomics Inc., Ethris GmbH, Bio-Techne Corporation. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.